Tsang et al.

1	Inflammation	Proteomic Profiling of Psychosis in Young Adults:	
	finalize and frequen	the ALCDAC birth cabert	

- 2 findings from the ALSPAC birth cohort
- 3
- 4 Authors:
- 5 Ruby S. M. Tsang^{1,2,3}
- 6 Nicholas J. Timpson^{1,2}
- 7 Golam M. Khandaker^{1,2,3,4}
- 8
- 9 Affiliations:
- 10 ¹ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
- ² Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
- ³ Centre for Academic Mental Health, Population Health Sciences, University of Bristol,
- 13 Bristol, UK
- ⁴ NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS
- 15 Foundation Trust, Bristol, UK
- 16
- 17 Corresponding author:
- 18 Ruby Tsang
- 19 Population Health Sciences, Bristol Medical School
- 20 Oakfield House, Oakfield Grove
- 21 Bristol BS8 2BN
- 22 United Kingdom
- 23 ruby.tsang@bristol.ac.uk
- 24
- 25 Declaration of Interest: None.

Tsang et al.

27 Abstract

28 Psychotic disorder is associated with altered levels of various inflammatory markers in blood, 29 but existing studies have typically focused on a few selected biomarkers, have not examined 30 specific symptom domains notably negative symptoms, and are based on individuals with 31 established/chronic illness. Based on data from young people aged 24 years from the Avon 32 Longitudinal Study of Parents and Children (ALSPAC), a UK birth cohort, we have examined 33 the associations of 67 plasma immune/inflammatory proteins assayed using the Olink Target 34 96 Inflammation panel with psychotic disorder, positive (any psychotic experiences and 35 definite psychotic experiences) and negative symptoms, using linear models with empirical 36 Bayes estimation. The analyses included between 2641 and 2854 individuals. After 37 adjustment for age, sex, body mass index and smoking and correction for multiple testing, 38 upregulation of CDCP1 and IL-6 were consistently associated with positive symptoms and 39 psychotic disorder, while psychotic disorder was additionally associated with upregulation of 40 MMP-10. Negative symptoms were associated with upregulation of the highest number of 41 proteins (n=11), including cytokines, chemokines and growth factors which partly overlap 42 with proteins associated with positive symptoms or psychotic disorder (CDCP1, IL-6 and 43 MMP-10). Our findings highlight associations of inflammatory proteins involved in immune 44 regulation, immune cell activation/migration, blood-brain barrier disruption, and extracellular 45 matrix abnormalities with psychosis or psychotic symptoms in young people, consistent with 46 a role of inflammation and immune dysfunction in the pathogenesis of psychotic disorders. 47

Keywords: ALSPAC; psychosis; proteomics; inflammation; inflammatory markers; positive
symptoms; negative symptoms

50

Tsang et al.

51 1. Introduction

52	Psychosis is an umbrella term that refers to a group of complex neuropsychiatric disorders
53	primarily characterized by positive (e.g., hallucinations, delusions, or confusion) and
54	negative symptoms (e.g., apathy and diminished expression). The median lifetime
55	prevalence for schizophrenia, the archetypal psychotic disorder, is 4.0 per 1000 persons
56	(McGrath et al., 2008), whereas it is 7.5 per 1000 persons for all psychoses (Moreno-
57	Küstner et al., 2018). In contrast, subthreshold psychosis-like experiences are relatively
58	common and are experienced by approximately a quarter of the general population during
59	their lifetime (Bourgin et al., 2020). It has been suggested that the psychosis phenotype is
60	expressed on a continuum, where symptoms may present in non-clinical populations (van
61	Os et al., 2009).
62	
63	Schizophrenia is a multifactorial condition with both genetic and environmental contributions.
64	Infection, inflammation and immune dysfunction have been implicated in the pathogenesis of
65	schizophrenia and related psychoses (Benros et al., 2011; Brown and Derkits, 2010;
66	Goldsmith et al., 2016; Khandaker et al., 2015). There is substantial evidence for cross-
67	sectional associations between central and peripheral inflammation and schizophrenia
68	spectrum disorders. Abnormal cerebrospinal fluid (CSF) markers were observed in
69	individuals with schizophrenia spectrum disorders, including elevated total protein, albumin
70	ratio, white blood cell count, glucose, IL-6 and IL-8 levels (Warren et al., 2024). Blood
71	concentrations of a number of inflammatory markers, namely interleukin (IL)-1 β , IL-1
72	receptor antagonist (IL-1RA), soluble IL-2 receptor (sIL-2R), IL-6, IL-8, IL-10, tumor necrosis
73	factor (TNF)- α , and C-reactive protein (CRP) were consistently elevated in individuals with
74	schizophrenia-spectrum disorder compared to healthy controls (Halstead et al., 2023).
75	Subsets of cytokines may be associated with specific features of the disorder, for instance
76	IL-2 and interferon (IFN)- γ were elevated in acute schizophrenia-spectrum disorder whereas
77	IL-4, IL-12 and IFN-γ were reduced in chronic schizophrenia-spectrum disorder (Halstead et
78	al., 2023); another study found elevated IL-6, IL-12, IL-17 and IFN-γ levels were observed in

Tsang et al.

79 antipsychotic-naïve first-episode psychosis (FEP) while elevated IL-1β, IL-2, IL-4, IL-6 and 80 TNF- α as well as reduced IL-10, were associated with negative symptoms (Dunleavy et al., 81 2022). Increased total white blood cell, monocyte and neutrophil counts were also observed 82 in schizophrenia and FEP (Jackson and Miller, 2020). Similar dysregulations of inflammatory 83 markers are also seen in those with subthreshold or transitory symptoms; when comparing 84 subgroups with familial risk and clinical risk of psychosis with controls, the clinical risk 85 subgroup showed higher IL-6 levels than controls, but the study did not find any evidence for 86 markers that predicted transition to psychosis (Misiak et al., 2021).

87

88 Longitudinally, exposures to inflammation during gestation and in childhood have been 89 shown to be associated with psychosis risk. Prenatal exposure to infections and elevated 90 proinflammatory cytokines may be associated with schizophrenia risk and structural and 91 functional brain abnormalities relevant to schizophrenia, though effects may differ by 92 infectious agent and timing of exposure (Khandaker et al., 2013). Furthermore, childhood 93 viral infections involving the central nervous system may be associated with an increased 94 risk of adult schizophrenia (Khandaker et al., 2012). Studies using data from the Avon 95 Longitudinal Study of Parents and Children (ALSPAC) also showed that circulating IL-6 and 96 CRP levels assessed in childhood and adolescence predicted psychosis or schizophrenia 97 risk in adulthood (Khandaker et al., 2014; Metcalf et al., 2017), suggesting that immune-98 inflammatory changes predate the onset of psychosis or schizophrenia. Two other studies 99 using ALSPAC data compared protein expression levels in childhood between those who did 100 and did not later develop psychotic experiences or disorder in early adulthood, and found 101 dysregulation of the complement and coagulation system was associated with psychosis risk 102 (English et al., 2017; Föcking et al., 2021).

103

Genome-wide association studies have identified multiple loci associated with schizophrenia
 risk, with strongest effects seen from variations in the major histocompatibility complex locus
 and particularly in complement component 4 genes, implicating immune function and

Tsang et al.

107	complement activity in the pathogenesis of schizophrenia (Sekar et al., 2016). Furthermore,
108	Mendelian randomization studies support a potentially causal role of IL-6 signaling in
109	schizophrenia, with increased levels of IL-6 and soluble IL-6 receptor (sIL-6R) associated
110	with a higher risk of schizophrenia; additionally, IL-6 appeared to explain the previously
111	reported protective effect of CRP (Hartwig et al., 2017; Perry et al., 2021).
112	
113	While existing studies support a role of inflammation in psychosis, there are key gaps in
114	knowledge. For instance, most existing studies have typically focused on a limited number of
115	inflammatory markers, but examining a larger immune proteomic panel can yield greater
116	system-level insights into the pathophysiology of psychosis. Negative symptoms are core to
117	schizophrenia, but there are relatively fewer studies of inflammation and negative symptoms
118	compared to that of positive symptoms (Dunleavy et al., 2022). Negative symptoms
119	represent an unmet clinical need as existing antipsychotic drugs do not adequately improve
120	these symptoms. There is some evidence that inflammatory markers are associated with
121	negative symptoms (Dunleavy et al., 2022; Khandaker et al., 2021); therefore, further studies
122	are needed to examine these associations to understand whether inflammation could be a
123	treatment target for negative symptoms. Finally, most existing studies are based on adults
124	with established psychotic disorder. Studies of people who are relatively early on in the
125	course of illness are required to identify immunological factors that are potentially relevant
126	for incidence, rather than chronicity/prognosis. Studies of young people are also
127	advantageous as this group is relatively unaffected by confounding from chronic
128	inflammation-related diseases of adulthood.
129	
130	We present a study examining the associations of a range of inflammatory proteins,
131	assessed using a proteomic panel, with psychotic disorder and positive and negative
132	symptoms of psychosis at age 24 years using data from the Avon Longitudinal Study of

133 Parents and Children (ALSPAC), a UK birth cohort. The aim of this study was to examine the

Tsang et al.

134 pl	lasma inflammator	y proteomic	profile of p	sychotic disorder,	and to compare	patterns of
--------	-------------------	-------------	--------------	--------------------	----------------	-------------

associations for positive and negative symptoms in young adults.

136

137 2. Materials and Methods

- 138 2.1. Cohort and sample selection
- 139 Pregnant women resident in Avon, United Kingdom with expected dates of delivery between
- 140 1st April 1991 and 31st December 1992 were invited to take part in the Avon Longitudinal
- 141 Study of Parents and Children (ALSPAC) (Boyd et al., 2012; Fraser et al., 2012; Northstone
- 142 et al., 2019). The initial number of pregnancies enrolled was 14,541 and 13,988 children
- 143 were alive at 1 year of age. Additional recruitment took place when the oldest children were
- approximately 7 years of age. The total sample size for analyses using any data collected
- 145 after the age of seven is therefore 15,447 pregnancies, with 14,901 children who were alive

146 at 1 year of age (Generation 1).

147

148 The present study focuses on the subset of Generation 1 participants who had data

- 149 available for the relevant exposures (psychotic experiences, psychotic disorder, or negative
- 150 symptoms), outcomes (blood immunological protein levels), and covariables (age, sex at
- 151 birth, body mass index [BMI], and smoking). The sample selection flow diagram is presented
- 152 in **Figure 1**.
- 153

154 Study data were collected and managed using Research Electronic Data Capture (REDCap)

155 electronic data capture tools hosted at the University of Bristol (Harris et al., 2009). REDCap

156 is a secure, web-based software platform designed to support data capture for research

157 studies. Please note that the study website contains details of all the data that is available

through a fully searchable data dictionary and variable search tool

159 (http://www.bristol.ac.uk/alspac/researchers/our-data/).

160

161 2.2. Ethics

Tsang et al.

- 162 Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee
- 163 and the Local Research Ethics Committees. Consent for biological samples has been
- 164 collected in accordance with the Human Tissue Act (2004). Informed consent for the use of
- 165 data collected via questionnaires and clinics was obtained from participants following the
- 166 recommendations of the ALSPAC Ethics and Law Committee at the time.

Tsang et al.



183 Figure 1. Flow diagram showing data availability in Generation 1 of ALSPAC for the

184 analyses conducted.

Tsang et al.

186 2.3. Psychosis-related measures at age 24

187 Psychotic experiences (PEs) and disorder were identified through the face-to-face, semi-188 structured Psychosis-Like Symptoms Interview (PLIKSi) administered by trained psychology 189 graduates. The PLIKSi consists of 12 core items derived from the Diagnostic Interview 190 Schedule for Children, Version IV (DISC-IV) (Shaffer et al., 2000) and the Schedules for 191 Clinical Assessment in Neuropsychiatry, Version 2.0 (SCAN 2.0) (World Health Organization 192 Division of Mental Health, 1994). These items assess the presence, frequency and context 193 of experiences associated with psychosis from three main domains of positive psychotic 194 symptoms: hallucinations (visual and auditory), delusions (spied on, persecution, thoughts 195 read, reference, control, grandiosity and other), and experiences of thought interference 196 (broadcasting, insertion and withdrawal). Coding of all items followed glossary definitions, 197 assessment, and rating rules for the SCAN 2.0. The PLIKSi administered at age 24 showed 198 good inter-rater and test-retest reliability (intraclass correlation=0.81 [95% CI = 0.68-0.89] 199 and intraclass correlation=0.90 [95% CI = 0.83-0.95]) (Sullivan et al., 2020).

200

Individuals who self-reported PEs were cross-questioned to verify the presence of each of these experiences, which were then rated by interviewers as: PEs not present, suspected PEs, or definite PEs. Cases of psychotic disorder were defined as having an interviewerrated definite PE not attributable to the effects of sleep or fever, with recurring symptoms of at least once a month over the prior 6 months, which the individual reported as either very distressing, or had a negative impact on their social or occupational life, or led them to seek professional help (Zammit et al., 2013).

208

209 Negative symptoms such as apathy, anergia and asociality were assessed using 10

210 questions based on the Community Assessment of Psychic Experiences (CAPE) self-report

211 questionnaire, where each item was rated on a 4-point scale (0=never; 1=sometimes;

212 2=often; 3=always) and summed. Missing items were handled with median replacement,

213 except where all items were missing, the sum score was coded as missing. We then derived

Tsang et al.

214	a binary variable based on the sum score, and we assigned those with a score of 14 or
215	above into the 'high negative symptoms' group (Jones et al., 2016); this corresponded to
216	13.9% of the sample.

217

218 For the set of analyses looking at positive symptoms, the exposures were: i) 'any PEs':

219 presence of any PEs, suspected or definite, not attributable to the effects of sleep or fever, ii)

220 'definite PEs': presence of any definite PEs not attributable to the effects of sleep or fever

and iii) psychotic disorder as described above. The control group was defined as those who

222 did not meet criteria for suspected/definite PEs or psychotic disorder. For the analysis

looking at negative symptoms, the exposure was presence of high negative symptoms.

224

225 2.4. Blood inflammatory proteins at age 24 years

Blood samples were collected in lithium heparin tubes and placed on ice until processing.
Samples were spun at 1300g for 10 minutes at 4-5°C, then plasma was aliquoted from the

tube and stored at -80°C. Target time from sample collection until plasma frozen was 90

229 minutes. Heparin-stored plasma samples collected from at approximately age 24 (fasting)

were analyzed using the Olink Target 96 Inflammation panel (Olink Analysis Service,

231 Uppsala, Sweden). The Olink Target 96 Inflammation panel measures a selection of 92

proteins involved in inflammatory and immune response processes. Data were returned in

233 Normalised Protein eXpression (NPX) values on a log₂ scale, which are calculated from

234 protein concentrations (cycle threshold [Ct] values) with normalization to minimize intra- and

inter-assay variation (Olink Proteomics, 2021). Further details on the proteins assayed and

236 quality control procedures applied have been previously reported (see data note by Goulding

et al., 2024).

238

239 Samples that did not pass Olink's quality control were excluded from the analysis. Proteins

- 240 with ≥50% values below the limit of detection (LOD) were excluded (based on values
- 241 reported in the relevant ALSPAC data note (Goulding et al., 2024); namely ARTN, Beta-NGF,

Tsang et al.

242	FGF-23,	FGF-5,	GDNF	, IL-1 al	pha,	IL-10RA	, IL-13	, IL-15RA	, IL-17A	, IL-2	, IL-20	, IL-20RA,	, IL-
	/					-	-	-	1	,	-		

243 22 RA1, IL-24, IL-2RB, IL-33, IL-4, IL-5, LIF, NRT, NT-3, SIRT2, SLAMF1, TSLP), leaving 67

proteins to be used as outcomes in the analyses (Table S1). NPX values beyond 5 standard

245 deviations (SD) from the mean were recoded as missing. No further normalization

246 procedures were applied to the proteomic data prior to analysis, as it will reduce information

available for the empirical Bayes estimation used in the analysis.

248

249 2.5. Covariables

BMI was computed using the formula: weight (kg) / height² (m²), and we recoded values of

251 <15 or >=60 as missing. Smoking was assessed via a questionnaire, and we derived a

composite smoking variable by coding those who self-reported having smoked in the past 30

253 days and \geq 1 cigarettes per day or \geq 7 per week as smokers.

254

255 2.6. Statistical analysis

256 Sociodemographic characteristics of cases and controls were summarized as n (%), mean

257 (standard deviation) or median [interquartile range] depending on the variable type

258 (continuous or categorical). Group comparisons were conducted using Fisher's exact tests

259 for categorical variables, *t*-tests for normally distributed continuous variables and Kruskal-

260 Wallis tests for non-normally distributed continuous variables.

261

262 Prior to analysis, correlations between inflammatory proteins were examined using

263 Spearman's rho (Figure S1) and a principal component analysis was performed to examine

the overall distribution of the data and identify potential sample clustering in the inflammation

- 265 proteomics panel. There was evidence for clustering effects by sex and BMI, but not by age,
- smoking, batch, or plate (Figure S2). Associations between each case definition and

267 inflammatory proteins were evaluated using multiple linear models fitted in the limma R

268 package (Ritchie et al., 2015), which uses an empirical Bayes method to moderate the

standard errors of the estimated log-fold changes by accounting for information from other

270	markers. For each of the case definitions, we ran a set of unadjusted models and a set of
271	adjusted models with age, sex at birth, BMI and smoking as covariables. Correction for
272	multiple comparisons was performed using the Benjamini-Hochberg procedure with a false
273	discovery rate (FDR) adjusted p -value threshold of <0.05. We did not apply a fold change
274	threshold as the effects are expected to be small in multifactorial phenotypes in a population-
275	based sample.
276	
277	We then examined protein-protein interactions (PPI) between the identified differentially
278	abundant proteins at the nominal $p < 0.05$ level (separately for positive and negative
279	symptoms) and functional enrichment in STRING database (version 12.0; https://string-
280	db.org) (Szklarczyk et al., 2019). We used 66 out of the 67 proteins included in the analysis
281	as the statistical background as STRING was not able to map VEGF-A to an entry in the
282	database.
283	
284	Data extraction and initial data cleaning was performed in StataMP 18 (StataCorp, 2023).
285	Further data preparation and statistical analyses were conducted in RStudio 2022.07.1 using
286	R v4.2.1 (R Core Team, 2022), using packages tidyverse (v2.0.0), haven (v2.5.2), reshape2
287	(v1.4.4), tableone (v0.13.2), and limma (v3.54.2). Plots were generated using ggplot2
288	(v3.4.2), ggfortify (v0.4.16), ggrepel (v0.9.3), and ggpubr (v0.6.0).
289	
290	3. Results
291	3.1. Sample characteristics
292	Characteristics of the controls (n=2574) and any PEs (n=280), definite PEs (n=169), and
293	psychotic disorder groups (n=67) at age 24 years from the ALSPAC birth cohort are
294	presented in Table 1. Group comparisons revealed individuals in the psychotic disorder
295	group were more likely to be female, those in the any PEs group were more likely to have
296	higher BMI and all case groups were more likely to be smokers and report higher negative
297	symptoms than controls. Comparisons between individuals with and without high negative
	12

Tsang et al.

- symptoms showed that individuals with high negative symptoms (n=390) were marginally
- 299 older, more likely to be smokers and less likely to have risky alcohol consumption than those
- 300 with low or no negative symptoms (**Table 2**).

Tsang et al.

302 Table 1. Sociodemographic and lifestyle characteristics of the included sample by

303 psychosis outcome

	Controls	Any PEs	Definite PEs	Psychotic
	(n=2574)	(n=280)	(n=169)	disorder
				(n=67)
Age (years), mean	24.03 (0.85)	24.11 (0.83)	24.10 (0.84)	24.06 (0.83)
(SD)				
Sex at birth	1623 (63.1%)	178 (63.6%)	111 (65.7%)	53 (79.1%)*
(female), n (%)				
BMI, mean (SD)	23.55 [21.45,	24.35 [21.44,	23.51 [21.26,	23.20 [20.29,
	26.68]	28.69]*	28.35]	28.66]
Smoking (Yes), n	690 (26.8%)	117	74 (43.8%)***	28 (41.8%)*
(%)		(41.8%)***		
AUDIT-C score,	5.00 [4.00,	5 [3.00, 7.00]	5.00 [3.00, 7.00]	5.00 [3.00,
median [IQR]	7.00]			6.25]
CAPE score,	6.00 [3.00,	10.00 [6.00,	11.00 [6.00,	12.50 [8.00,
median [IQR]	10.00]	15.00]***	16.25]***	19.00]***

304

305 Note: Group comparisons were conducted using chi-square tests for categorical variables, t-

306 test for normally distributed continuous variables and Kruskal-Wallis tests for non-normally

307 distributed continuous variables. *p<0.05, **p<0.01, ***p<0.001.

308 Abbreviations: BMI – body mass index; CAPE – Community Assessment of Psychic

309 Experiences; IQR - interquartile range

Tsang et al.

311 Table 2. Sociodemographic and lifestyle characteristics by level of negative

312 symptoms

	No/low negative symptoms	High negative symptoms
	(CAPE score < 14)	(CAPE score ≥ 14)
	(n = 2409)	(n = 390)
Age (years), mean (SD)	24.03 (0.84)	24.12 (0.87)*
Sex at birth (female), n (%)	1535 (63.7%)	233 (59.7%)
BMI, mean (SD)	23.58 [21.48, 26.64]	23.81 [21.16, 28.19]
Smoking (Yes), n (%)	646 (26.8%)	142 (36.4%)***
AUDIT-C score, median	5.00 [4.00, 7.00]	5.00 [3.00, 6.00]***
[IQR]		

313

314 Note: Group comparisons were conducted using chi-square tests for categorical variables, t-

315 test for normally distributed continuous variables and Kruskal-Wallis tests for non-normally

316 distributed continuous variables. *p<0.05, **p<0.01, ***p<0.001.

317 Abbreviations: BMI – body mass index; IQR – interquartile range

Tsang et al.

319	3.2. Differentially abundant inflammatory proteins in psychosis and related outcomes
320	The condition 'any PEs' was associated with upregulation of 22 inflammatory proteins after
321	covariable adjustment; p-values of 6 of these associations survived FDR correction, which
322	are CUB domain-containing protein 1 (CDCP1), TNF-related apoptosis-inducing ligand
323	(TRAIL), IL-6, hepatocyte growth factor (HGF), monocyte chemoattractant protein-1 (MCP-1)
324	and vascular endothelial growth factor A (VEGF-A) (Figure 2B). Definite PEs were
325	associated with upregulation of 17 proteins after covariable adjustment, but only CDCP1 and
326	IL-6 survived FDR correction (Figure 2B). Psychotic disorder was associated with
327	upregulation of 11 proteins after covariable adjustment and evidence for three of these
328	proteins, namely CDCP1, IL-6 and matrix metalloproteinase-10 (MMP-10), remained after
329	FDR correction (Figure 2B). Full results for each of these models can be found in the
330	Supplementary Material.
331	
332	High negative symptoms were associated with upregulation of 23 proteins after covariable
333	adjustment, 11 of which survived FDR correction. These proteins were HGF, MMP-10, IL-6,
334	CDCP1, C-C motif chemokine ligand (CCL) 11, TRAIL, C-X3-C motif chemokine ligand 1
335	(CX3CL1), Fms-related receptor tyrosine kinase 3 ligand (FLT3L), fibroblast growth factor 21

336 (FGF-21), IL-10 receptor subunit beta (IL-10RB), CCL25 (Table 3). Full results can be found

- in the **Supplementary Material**.
- 338

A total of 15 proteins showed upregulation in both positive and negative symptoms (using the nominal *p*-value cutoff of 0.05), which are CCL11, CCL25, T-cell surface glycoprotein CD5 (CD5), FGF-19, FGF-21, HGF, IL-6, latency-associated peptide transforming growth factor beta-1 (LAP TGF- β 1), MCP-1, MMP-10, stem cell factor (SCF), transforming growth factor alpha (TGF- α), tumor necrosis factor receptor superfamily member 9 (TNFRSF9), and TRAIL.

345

346 **3.3. Protein-protein interactions (PPI) and functional enrichment**

- 347 Most identified differentially abundant proteins were functionally associated with each other
- 348 within the protein-protein interaction network, suggesting they jointly contribute to shared
- 349 functions (**Figures S3-S4**). However, the network showed no evidence of PPI or functional
- 350 enrichment of Gene Ontology terms against the statistical background of the included list of
- 351 proteins.



352

353

medRxiv preprint doi: https://doi.org/10.1101/2024.04.29.24306568; this version posted May 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Tsang et al.

354 Figure 2. Differentially abundant blood inflammatory proteins associated with any psychotic experiences not attributable to sleep or

- 355 fever, definite psychotic experiences not attributable to sleep or fever, and psychotic disorder.
- 356 Panels A and B show results from unadjusted and adjusted models respectively. The labelled points are proteins that reach a nominal *p* < 0.05,
- 357 and those in orange indicates upregulated proteins that survived FDR correction.

Tsang et al.

358 Table 3. Inflammatory proteins associated with high negative symptoms, before and

359 after FDR correction.

Protein	Log ₂ fold	Fold	t-statistic	p-value	FDR adjusted
	change	change			p-value
HGF	0.07	1.05	4.07	4.78e-5	3.20e-3
MMP-10	0.13	1.10	3.85	1.18e-4	3.97e-3
IL-6	0.13	1.10	3.69	2.27e-4	5.08e-3
CDCP1	0.08	1.06	3.60	3.23e-4	5.41e-3
CCL11	0.05	1.04	3.41	6.58e-4	8.82e-3
TRAIL	0.06	1.04	3.32	9.22e-4	1.03e-2
CX3CL1	0.07	1.05	3.27	1.08e-3	1.03e-2
FLT3L	0.07	1.05	2.98	2.94e-3	2.22e-2
FGF-21	0.22	1.17	2.97	2.98e-3	2.22e-2
IL-10RB	0.05	1.03	2.88	4.06e-3	2.72e-2
CCL25	0.09	1.06	2.69	7.22e-3	4.40e-2
IL-18R1	0.06	1.04	2.58	9.92e-3	5.42e-2
SCF	0.06	1.04	2.56	1.05e-2	5.42e-2
CCL19	0.09	1.06	2.47	1.37e-2	6.56e-2
TGF-α	0.03	1.02	2.39	1.67e-2	7.46e-2
CD5	0.04	1.03	2.37	1.79e-2	7.50e-2
TWEAK	0.05	1.03	2.32	2.06e-2	8.12e-2
MCP-1	0.05	1.03	2.20	2.79e-2	9.99e-2
CCL20	0.10	1.08	2.19	2.83e-2	9.99e-2
FGF-19	0.10	1.07	2.05	4.02e-2	1.34e-1
IL-18	0.06	1.04	2.03	4.21e-2	1.34e-1
TNFRSF9	0.04	1.03	2.00	4.53e-2	1.34e-1
LAP TGF-	0.03	1.02	1.99	4.52e-2	1.34e-1

Tsang et al.

	beta1	
360		

Tsang et al.

362 4. Discussion

363 Our study aimed to identify the plasma immune-inflammatory proteomic profile of psychotic 364 disorder and related outcomes (positive and negative symptoms) in young adults using data 365 from a well-phenotyped birth cohort. We observed upregulation of six, two and three proteins 366 in any PEs, definite PEs and psychotic disorder respectively after covariable adjustment and 367 FDR correction; 368 CDCP1 and IL-6 were common to all three positive symptom case definitions and psychotic 369 disorder was additionally associated with upregulation of MMP-10. We found upregulation of 370 11 protein in those with high negative symptoms, including CDCP1, IL-6 and MMP-10. 371 These alterations were of relatively small magnitude, with many showing less than 10% 372 upregulation, but more substantial fold changes were seen in the psychotic disorder group, 373 where there were between 17% and 26% increases in CDCP1, IL-6 and MMP-10 levels. We 374 observed alterations in different types of proteins, including growth factors, cytokines, 375 chemokines, and matrix metalloproteinases that play roles in immune regulation, T cell 376 activation and migration, macrophage activation and potentially blood-brain barrier (BBB) 377 disruption, suggesting widespread immunological alterations are involved in psychosis. 378 379 We report consistent evidence for associations of IL-6 across all psychosis-related outcomes 380 examined including positive, negative symptoms and psychotic disorder. IL-6 is a pleiotropic 381 cytokine that plays a key role in the regulation of immune responses and inflammation. As 382 the most frequently studied cytokine, there is considerable evidence that suggests circulating 383 concentrations of IL-6 is elevated across the psychosis spectrum, including in those at risk of 384 psychosis (Misiak et al., 2021), in antipsychotic-naïve FEP (Dunleavy et al., 2022) and in 385 both acute and chronic schizophrenia spectrum disorder (Halstead et al., 2023). IL-6 has 386 also been reported to be associated with negative symptoms (Dunleavy et al., 2022). Our 387 findings support an ongoing clinical trial investigating whether inhibition of IL-6 signaling

388 using an anti-IL6R monoclonal antibody, tocilizumab, improves negative symptoms in people

389 with psychosis (Foley et al., 2023). Due to the pleiotropic effects of IL-6, the specific

Tsang et al.

390	mechanisms underlying the associations between increased IL-6 and psychosis remain
391	poorly understood and further research is required to elucidate the specific biological
392	pathways and cascades involved.

393

394 CDCP1 is a transmembrane glycoprotein with three extracellular CUB domains. It has 395 typically been studied in the context of cancer due to its overexpression in solid tumors and 396 is considered a key regulator of cancer metastasis through its roles in cell migration and 397 invasion, and extracellular matrix degradation via MMP-9 secretion (Miyazawa et al., 2010). 398 More recently, CDCP1 has been found to have immune regulatory roles; it is a ligand for 399 CD6 and regulates T cell activation and migration (Envindah-Asonye et al., 2017), and 400 reduced IL-6 production was observed in CDCP1 knockout mice in an animal model of 401 Kawasaki disease (Lun et al., 2021). CDCP1 has been shown to participate in a CD6 402 tripartite receptor complex that induces cytoskeleton remodeling and cell barrier tight 403 junction reduction in retinal pigment epithelium cells (Borjini et al., 2023), suggesting this 404 process may underlie disruptions to tissue barriers caused by T cell-mediated inflammation. 405 It is possible that this process also contributes to disrupted BBB and T cell infiltration into the 406 central nervous system, leading to neuroinflammation and neuropsychiatric disorders such 407 as psychosis and schizophrenia spectrum disorders.

408

409 MMPs are a family of zinc-dependent endopeptidases that contribute to tissue remodeling by 410 degradation of extracellular matrix components in normal physiological processes and 411 pathological conditions. In recent years, MMP-9 emerged as a candidate involved the 412 pathophysiology of schizophrenia, as it is known to regulate a range of neurodevelopmental 413 processes including synaptic and dendritic spine plasticity, neuroinflammation and BBB 414 permeability (Bitanihirwe and Woo, 2020; Chopra et al., 2019). Although studies examining 415 the candidate functional single nucleotide polymorphism (SNP) -1562 C/T polymorphism 416 (rs3918242) in the MMP9 gene reported conflicting results (Xia et al., 2019), there is

Tsang et al.

417 evidence for peripheral MMP-9 upregulation in schizophrenia spectrum disorders

418 (Schoretsanitis et al., 2021).

419

420	MMP-10, also known as stromelysin-2, is expressed by macrophages in response to injury,
421	infection or transformation; it is a critical mediator of macrophage activation (McMahan et al.,
422	2016) and has been shown to promote chronic inflammation (Sánchez et al., 2022). MMP-10
423	has rarely been studied in the context of neuropsychiatric disorders, and the limited literature
424	has reported mixed findings in relation to schizophrenia. One study reported that elevated
425	CSF MMP-10 levels were associated with major depressive disorder, but not schizophrenia
426	(Omori et al., 2020); however, another study reported associations between epigenetic
427	proxies of plasma concentrations of MMP-10 and clinical features of schizophrenia
428	(Kiltschewskij et al., 2024). It has also been shown in vitro that MMP-10 can activate MMP-9
429	via proteolysis of its precursor pro-MMP9 (Nakamura et al., 1998) and thus may be involved
430	in a cascade that impacts on neurodevelopment and neuroinflammation in psychosis and
431	schizophrenia spectrum disorders.
432	

433 The novel markers of CDCP1 and MMP-10 suggest potential roles of BBB dysfunction and 434 extracellular matrix abnormalities in the pathophysiology of psychosis. Neuroinflammation 435 has been shown to contribute to neurovascular endothelial dysfunction and increased BBB 436 permeability in schizophrenia (Najjar et al., 2017). Extracellular matrix abnormalities, 437 including reduced perineuronal nets and reduced extracellular matrix gene expression in 438 several brain regions (Pantazopoulos et al., 2021) and alterations in brain extracellular 439 matrix composition (Rodrigues-Amorim et al., 2022) have also been reported in 440 schizophrenia. Further research is required to better understand the cascade of events 441 including disruption of BBB integrity and extracellular matrix abnormalities in the 442 pathogenesis of psychosis.

443

Tsang et al.

444	As a result of the cross-sectional design used here, we cannot ascertain whether any of the
445	protein associations are causal for psychosis. However, we looked up evidence of potential
446	causality based on existing Mendelian randomization (MR) studies which use genetic
447	variants as instrumental variables to assess whether the association between an exposure
448	and an outcome is likely to be causal or result of residual confounding or reverse causation
449	(Sanderson et al., 2022). Existing MR studies support a potential causal role of IL-6 in
450	schizophrenia (Hartwig et al., 2017; Perry et al., 2021), with also weak evidence of MCP-1
451	(Perry et al., 2021) that was associated with both positive and negative symptoms in the
452	present study. In addition, a more recent MR study involving 735 immune-related biomarkers
453	reported MR evidence for potential causal effects with schizophrenia for several proteins we
454	found to be associated with psychosis/psychotic symptoms in our sample. These include IL-
455	6, IL-10RB, IL-18, LIF-R, CCL25, FGF-19, and MMP-10 (Dardani et al., 2024). In particular,
456	the study by Dardani and colleagues reported stronger evidence of causality for FGF-19 and
457	MMP-10, though the interpretation may be complicated due to the use of potentially complex
458	genetic instruments derived from trans quantitative trait loci (trans-QTLs) associations. In
459	addition, FGF19 also showed evidence of genetic colocalization whereby the locus
460	associated with blood FGF-19 protein levels were also associated with schizophrenia (Zuber
461	et al., 2022). Taken together, findings from our analysis reported here and existing MR
462	studies suggest that FGF-19 and MMP-10 could be causally relevant for schizophrenia.
463	These proteins (along with others highlighted by our study and existing MR studies) require
464	further investigation.
465	
466	Strengths of this study include using detailed blood immune proteomic data, various

467 psychosis-related outcomes across the psychosis spectrum as well as examining both

468 positive and negative symptoms, as well as using a population-based young adult sample.

469 There are several limitations to the existing study. Firstly, this study is cross-sectional in

470 design, making it difficult to ascertain whether any observed associations are causal or result

471 of reverse causality or residual confounding. Further research is required to replicate these

Tsang et al.

472	associations, determine the temporal order of events and investigate whether these
473	associations are causal. Secondly, as the study sample is drawn from a population-based
474	cohort, there is likely a larger degree of heterogeneity in symptom severity, phase, duration,
475	psychotropic medication use and neuropsychiatric comorbidity within the case groups, for
476	which we have not been able to adjust despite their potential effects on blood protein levels.
477	Lastly, the case groups defined by positive symptoms are rather small and the analyses may
478	be underpowered to detect smaller effects, which may explain why only few signals were
479	found relative to the analysis involving negative symptoms.

480

481 5. Conclusions

482 Using data from a well characterized birth cohort, we report that IL-6 and CDCP1 are

483 associated with psychotic disorder and positive symptoms of psychosis, while negative

484 symptoms are associated with changes in a larger number of immune proteins which partly

485 overlap with proteins associated with positive symptoms. In addition to IL-6 that is already

486 well reported in the literature, we identified two novel inflammatory markers, CDCP1 and

487 MMP-10, which are implicated in immune regulation, T cell activation and migration,

488 macrophage activation, BBB disruption, and extracellular matrix abnormalities. Our findings

489 suggest there are widespread alterations in different types of inflammatory markers in young

490 people with psychosis or psychotic symptoms. This is consistent with a role of inflammation

and immune dysfunction in the pathogenesis of psychotic disorders.

492

Tsang et al.

493	F	u	n	d	i	n	a
100		ч	••	S		••	э

494	RSMT is supported by the Tackling Multimorbidity at Scale Strategic Priorities Fund
495	programme (MR/W014416/1) delivered by the Medical Research Council and the National
496	Institute for Health Research in partnership with the Economic and Social Research Council
497	and in collaboration with the Engineering and Physical Sciences Research Council. NJT is
498	the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z).
499	GMK acknowledges funding support from the Medical Research Council (MRC), UK
500	(MC_UU_00032/06) which forms part of the Integrative Epidemiology Unit (IEU) at the
501	University of Bristol. GMK acknowledges additional funding support from the Wellcome Trust
502	(201486/Z/16/Z and 201486/B/16/Z), MRC (MR/W014416/1; MR/S037675/1; and
503	MR/Z50354X/1), and the UK National Institute of Health and Care Research (NIHR) Bristol
504	Biomedical Research Centre (NIHR 203315). The views expressed are those of the authors
505	and not necessarily those of the NIHR or the Department of Health and Social Care, UK.
506	
507	The UK Medical Research Council (MRC) and Wellcome (grant ref: 217065/Z/19/Z) and the
508	University of Bristol provide core support for ALSPAC. This publication is the work of the
509	authors and RSMT and GMK will serve as guarantors for the contents of this paper. A
510	comprehensive list of grants funding is available on the ALSPAC website
511	(http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). Data
512	collection on psychotic symptoms at the age 24 research clinic was specifically funded by
513	the MRC (grant: MR/M006727/1) awarded to Prof. Stan Zammit.
514	
515	The funders had no involvement in study design; in the collection, analysis and interpretation
516	of data; in the writing of the report; or in the decision to submit the article for publication.
517	
518	CRediT authorship contribution statement
519	Ruby Tsang: Conceptualization, Formal analysis, Writing – original draft, Writing – review &

27

520

editing

Tsang et al.

- 521 Nicholas Timpson: Conceptualization, Writing review & editing, Supervision
- 522 Golam Khandaker: Conceptualization, Writing review & editing, Supervision

523

524 Acknowledgements

- 525 We are extremely grateful to all the families who took part in this study, the midwives for their
- 526 help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer
- 527 and laboratory technicians, clerical workers, research scientists, volunteers, managers,
- 528 receptionists and nurses.

Tsang et al.

530 References

- 531 Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B.,
- 532 2011. Autoimmune Diseases and Severe Infections as Risk Factors for Schizophrenia: A 30-
- 533 Year Population-Based Register Study. American Journal of Psychiatry 168, 1303-1310.
- 534 Bitanihirwe, B.K.Y., Woo, T.-U.W., 2020. A conceptualized model linking matrix
- 535 metalloproteinase-9 to schizophrenia pathogenesis. Schizophrenia Research 218, 28-35.
- 536 Borjini, N., Lun, Y., Jang, G.-F., Crabb, J., Chen, Y., Crabb, J., Fox, D.A., Ivanov, A.I., Lin, F.,
- 537 2023. CD6 triggers actomyosin cytoskeleton remodeling after binding to its receptor complex.
- 538 Journal of Leukocyte Biology 115, 450-462.
- 539 Bourgin, J., Tebeka, S., Mallet, J., Mazer, N., Dubertret, C., Le Strat, Y., 2020. Prevalence
- and correlates of psychotic-like experiences in the general population. Schizophrenia
- 541 Research 215, 371-377.
- 542 Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness,
- 543 A., Ring, S., Davey Smith, G., 2012. Cohort Profile: The 'Children of the 90s'—the index
- offspring of the Avon Longitudinal Study of Parents and Children. International Journal of
 Epidemiology 42, 111-127.
- 546 Brown, A.S., Derkits, E.J., 2010. Prenatal Infection and Schizophrenia: A Review of
- 547 Epidemiologic and Translational Studies. American Journal of Psychiatry 167, 261-280.
- 548 Chopra, S., Overall, C.M., Dufour, A., 2019. Matrix metalloproteinases in the CNS:
- 549 interferons get nervous. Cellular and Molecular Life Sciences 76, 3083-3095.

Tsang et al.

- 550 Dardani, C., Robinson, J.W., Jones, H.J., Rai, D., Stergiakouli, E., Grove, J., Gardner, R.,
- 551 McIntosh, A.M., Havdahl, A., Hemani, G., Smith, G.D., Richardson, T.G., Gaunt, T.R.,
- 552 Khandaker, G.M., 2024. Immunological Drivers and Potential Novel Drug Targets for Major
- 553 Psychiatric, Neurodevelopmental, and Neurodegenerative Conditions. medRxiv,
- 554 2024.2002.2016.24302885.
- 555 Dunleavy, C., Elsworthy, R.J., Upthegrove, R., Wood, S.J., Aldred, S., 2022. Inflammation in
- 556 first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of
- 557 negative symptoms, a systematic review and meta-analysis. Acta Psychiatrica Scandinavica

558 146, 6-20.

- 559 English, J.A., Lopez, L.M., O'Gorman, A., Föcking, M., Hryniewiecka, M., Scaife, C.,
- 560 Sabherwal, S., Wynne, K., Dicker, P., Rutten, B.P.F., Lewis, G., Zammit, S., Cannon, M.,
- 561 Cagney, G., Cotter, D.R., 2017. Blood-Based Protein Changes in Childhood Are Associated
- 562 With Increased Risk for Later Psychotic Disorder: Evidence From a Nested Case–Control
- 563 Study of the ALSPAC Longitudinal Birth Cohort. Schizophrenia Bulletin 44, 297-306.
- 564 Envindah-Asonye, G., Li, Y., Ruth, J.H., Spassov, D.S., Hebron, K.E., Zijlstra, A., Moasser,
- 565 M.M., Wang, B., Singer, N.G., Cui, H., Ohara, R.A., Rasmussen, S.M., Fox, D.A., Lin, F.,
- 566 2017. CD318 is a ligand for CD6. Proceedings of the National Academy of Sciences 114,

567 E6912-E6921.

- 568 Föcking, M., Sabherwal, S., Cates, H.M., Scaife, C., Dicker, P., Hryniewiecka, M., Wynne, K.,
- 569 Rutten, B.P.F., Lewis, G., Cannon, M., Nestler, E.J., Heurich, M., Cagney, G., Zammit, S.,
- 570 Cotter, D.R., 2021. Complement pathway changes at age 12 are associated with psychotic
- 571 experiences at age 18 in a longitudinal population-based study: evidence for a role of stress.
- 572 Molecular Psychiatry 26, 524-533.

- 573 Foley, É.M., Griffiths, S.L., Murray, A., Rogers, J., Corsi-Zuelli, F., Hickinbotham, H., Warwick,
- 574 E., Wilson, M., Kaser, M., Murray, G.K., Deakin, B., Jadon, D., Suckling, J., Barnes, N.M.,
- 575 Upthegrove, R., Khandaker, G.M., 2023. Protocol for the Psychosis Immune Mechanism
- 576 Stratified Medicine (PIMS) trial: a randomised double-blind placebo-controlled trial of single-
- 577 dose tocilizumab in patients with psychosis. BMJ Open 13, e067944.
- 578 Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G.,
- Henderson, J., Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M., Lawlor, D.A., 2012.
- 580 Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers
- 581 cohort. International Journal of Epidemiology 42, 97-110.
- 582 Goldsmith, D.R., Rapaport, M.H., Miller, B.J., 2016. A meta-analysis of blood cytokine
- 583 network alterations in psychiatric patients: comparisons between schizophrenia, bipolar
- disorder and depression. Molecular Psychiatry 21, 1696-1709.
- 585 Goulding, N., Goudswaard, L., Hughes, D., Corbin, L., Groom, A., Ring, S., Timpson, N.,
- 586 Fraser, A., Northstone, K., Suderman, M., 2024. Inflammation proteomics datasets in the
- 587 ALSPAC cohort [version 2; peer review: 2 approved]. Wellcome Open Research 7.
- 588 Halstead, S., Siskind, D., Amft, M., Wagner, E., Yakimov, V., Shih-Jung Liu, Z., Walder, K.,
- 589 Warren, N., 2023. Alteration patterns of peripheral concentrations of cytokines and
- 590 associated inflammatory proteins in acute and chronic stages of schizophrenia: a systematic
- review and network meta-analysis. The Lancet Psychiatry 10, 260-271.
- 592 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., 2009. Research
- 593 electronic data capture (REDCap)—A metadata-driven methodology and workflow process
- 594 for providing translational research informatics support. Journal of Biomedical Informatics 42,
- 595 377-381.

- 596 Hartwig, F.P., Borges, M.C., Horta, B.L., Bowden, J., Davey Smith, G., 2017. Inflammatory
- 597 Biomarkers and Risk of Schizophrenia: A 2-Sample Mendelian Randomization Study. JAMA
- 598 Psychiatry 74, 1226-1233.
- 599 Jackson, A.J., Miller, B.J., 2020. Meta-analysis of total and differential white blood cell counts
- 600 in schizophrenia. Acta Psychiatrica Scandinavica 142, 18-26.
- Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M., Holmans, P.,
- Lewis, G., Linden, D.E.J., Jones, P.B., Davey Smith, G., O'Donovan, M.C., Owen, M.J.,
- 603 Walters, J.T., Zammit, S., 2016. Phenotypic Manifestation of Genetic Risk for Schizophrenia
- 604 During Adolescence in the General Population. JAMA Psychiatry 73, 221-228.
- 605 Khandaker, G.M., Cousins, L., Deakin, J., Lennox, B.R., Yolken, R., Jones, P.B., 2015.
- 606 Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.
- 607 The Lancet Psychiatry 2, 258-270.
- 608 Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of
- 609 Serum Interleukin 6 and C-Reactive Protein in Childhood With Depression and Psychosis in
- 610 Young Adult Life: A Population-Based Longitudinal Study. JAMA Psychiatry 71, 1121-1128.
- 611 Khandaker, G.M., Stochl, J., Zammit, S., Lewis, G., Dantzer, R., Jones, P.B., 2021.
- 612 Association between circulating levels of C-reactive protein and positive and negative
- 613 symptoms of psychosis in adolescents in a general population birth cohort. Journal of
- 614 Psychiatric Research 143, 534-542.
- 615 Khandaker, G.M., Zimbron, J., Dalman, C., Lewis, G., Jones, P.B., 2012. Childhood infection
- and adult schizophrenia: A meta-analysis of population-based studies. Schizophrenia
- 617 Research 139, 161-168.

Tsang et al.

- 618 Khandaker, G.M., Zimbron, J., Lewis, G., Jones, P.B., 2013. Prenatal maternal infection,
- 619 neurodevelopment and adult schizophrenia: a systematic review of population-based studies.
- 620 Psychological Medicine 43, 239-257.
- 621 Kiltschewskij, D.J., Reay, W.R., Geaghan, M.P., Atkins, J.R., Xavier, A., Zhang, X., Watkeys,
- 622 O.J., Carr, V.J., Scott, R.J., Green, M.J., Cairns, M.J., 2024. Alteration of DNA Methylation
- and Epigenetic Scores Associated With Features of Schizophrenia and Common Variant
- 624 Genetic Risk. Biological Psychiatry 95, 647-661.
- Lun, Y., Borjini, N., Miura, N.N., Ohno, N., Singer, N.G., Lin, F., 2021. CDCP1 on Dendritic
- 626 Cells Contributes to the Development of a Model of Kawasaki Disease. The Journal of
- 627 Immunology 206, 2819-2827.
- 628 McGrath, J., Saha, S., Chant, D., Welham, J., 2008. Schizophrenia: A Concise Overview of

629 Incidence, Prevalence, and Mortality. Epidemiologic Reviews 30, 67-76.

- 630 McMahan, R.S., Birkland, T.P., Smigiel, K.S., Vandivort, T.C., Rohani, M.G., Manicone, A.M.,
- 631 McGuire, J.K., Gharib, S.A., Parks, W.C., 2016. Stromelysin-2 (MMP10) Moderates
- Inflammation by Controlling Macrophage Activation. The Journal of Immunology 197, 899-909.
- 634 Metcalf, S.A., Jones, P.B., Nordstrom, T., Timonen, M., Mäki, P., Miettunen, J., Jääskeläinen,
- 635 E., Järvelin, M.-R., Stochl, J., Murray, G.K., Veijola, J., Khandaker, G.M., 2017. Serum C-
- 636 reactive protein in adolescence and risk of schizophrenia in adulthood: A prospective birth
- 637 cohort study. Brain, Behavior, and Immunity 59, 253-259.

638	Misiak, B.	, Bartoli, F.,	Carrà, G	G., Stańczy	/kiewicz, B.,	Gładka, A.,	Frydecka, [D., Samochowiec,
	/	, , , ,			, ,		1	, ,

- J., Jarosz, K., Hadryś, T., Miller, B.J., 2021. Immune-inflammatory markers and psychosis
- risk: A systematic review and meta-analysis. Psychoneuroendocrinology 127, 105200.
- 641 Miyazawa, Y., Uekita, T., Hiraoka, N., Fujii, S., Kosuge, T., Kanai, Y., Nojima, Y., Sakai, R.,
- 642 2010. CUB Domain–Containing Protein 1, a Prognostic Factor for Human Pancreatic
- 643 Cancers, Promotes Cell Migration and Extracellular Matrix Degradation. Cancer Research
- 644 70, 5136-5146.
- 645 Moreno-Küstner, B., Martín, C., Pastor, L., 2018. Prevalence of psychotic disorders and its
- 646 association with methodological issues. A systematic review and meta-analyses. PLOS ONE
- 647 13, e0195687.
- Najjar, S., Pahlajani, S., De Sanctis, V., Stern, J.N.H., Najjar, A., Chong, D., 2017.
- 649 Neurovascular Unit Dysfunction and Blood–Brain Barrier Hyperpermeability Contribute to
- 650 Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence.
- 651 Frontiers in Psychiatry 8.
- 652 Nakamura, H., Fujii, Y., Ohuchi, E., Yamamoto, E., Okada, Y., 1998. Activation of the
- 653 precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases.
- European Journal of Biochemistry 253, 67-75.
- Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., Wells, N., 2019.
- 656 The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled
- sample of index children in 2019 [version 1; peer review: 2 approved]. Wellcome Open
- 658 Research 4.
- 659 Olink Proteomics, 2021. White paper: Data normalization and standardization.

Tsang et al.

- 660 Omori, W., Hattori, K., Kajitani, N., Okada-Tsuchioka, M., Boku, S., Kunugi, H., Okamoto, Y.,
- 661 Takebayashi, M., 2020. Increased Matrix Metalloproteinases in Cerebrospinal Fluids of
- 662 Patients With Major Depressive Disorder and Schizophrenia. International Journal of
- 663 Neuropsychopharmacology 23, 713-720.
- Pantazopoulos, H., Katsel, P., Haroutunian, V., Chelini, G., Klengel, T., Berretta, S., 2021.
- 665 Molecular signature of extracellular matrix pathology in schizophrenia. European Journal of
- 666 Neuroscience 53, 3960-3987.
- 667 Perry, B.I., Upthegrove, R., Kappelmann, N., Jones, P.B., Burgess, S., Khandaker, G.M.,
- 668 2021. Associations of immunological proteins/traits with schizophrenia, major depression
- and bipolar disorder: A bi-directional two-sample mendelian randomization study. Brain,
- 670 Behavior, and Immunity 97, 176-185.
- R Core Team, 2022. R: A language and environment for statistical computing. R Foundation
 for Statistical Computing, Vienna, Austria.
- 673 Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., 2015. limma

674 powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic

- 675 Acids Research 43, e47-e47.
- 676 Rodrigues-Amorim, D., Rivera-Baltanás, T., Fernández-Palleiro, P., Iglesias-Martínez-
- 677 Almeida, M., Freiría-Martínez, L., Jarmardo-Rodriguez, C., del Carmen Vallejo-Curto, M.,
- Álvarez-Ariza, M., López-García, M., de las Heras, E., García-Caballero, A., Olivares, J.M.,
- 679 Spuch, C., 2022. Changes in the Brain Extracellular Matrix Composition in schizophrenia: A
- 680 Pathophysiological Dysregulation and a Potential Therapeutic Target. Cellular and Molecular
- 681 Neurobiology 42, 1921-1932.

- 682 Sánchez, K.E., Bhaskar, K., Rosenberg, G.A., 2022. Apoptosis-associated speck-like protein
- 683 containing a CARD-mediated release of matrix metalloproteinase 10 stimulates a change in
- 684 microglia phenotype. Frontiers in Molecular Neuroscience 15.
- 685 Sanderson, E., Glymour, M.M., Holmes, M.V., Kang, H., Morrison, J., Munafò, M.R., Palmer,
- T., Schooling, C.M., Wallace, C., Zhao, Q., Davey Smith, G., 2022. Mendelian randomization.
- 687 Nature Reviews Methods Primers 2, 6.
- 688 Schoretsanitis, G., de Filippis, R., Ntogka, M., Leucht, S., Correll, C.U., Kane, J.M., 2021.
- 689 Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum
- Disorders: A Systematic Review and Meta-Analysis. Schizophrenia Bulletin 47, 986-996.
- 691 Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K.,
- 692 Presumey, J., Baum, M., Van Doren, V., Genovese, G., Rose, S.A., Handsaker, R.E., Daly,
- 693 M.J., Carroll, M.C., Stevens, B., McCarroll, S.A., Schizophrenia Working Group of the
- 694 Psychiatric Genomics, C., 2016. Schizophrenia risk from complex variation of complement
- 695 component 4. Nature 530, 177-183.
- 696 Shaffer, D., Fisher, P., Lucas, C.P., Dulcan, M.K., Schwab-Stone, M.E., 2000. NIMH
- 697 Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): Description,
- 698 Differences From Previous Versions, and Reliability of Some Common Diagnoses. Journal of
- the American Academy of Child & Adolescent Psychiatry 39, 28-38.
- StataCorp, 2023. Stata Statistical Software: Release 18. StataCorp LLC, College Station, TX,USA.
- 702 Sullivan, S.A., Kounali, D., Cannon, M., David, A.S., Fletcher, P.C., Holmans, P., Jones, H.,
- Jones, P.B., Linden, D.E.J., Lewis, G., Owen, M.J., O'Donovan, M., Rammos, A., Thompson,

704	A., Wolke,	D., Heron,	J., Zammit, S.	, 2020. A Po	pulation-Based	Cohort Study	Examining the
-	, ,	/ /	- ,	,			

- 705 Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and
- 706 Prediction of Psychotic Disorder. American Journal of Psychiatry 177, 308-317.
- 707 Szklarczyk, D., Gable, A.L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M.,
- Doncheva, N.T., Morris, J.H., Bork, P., Jensen, L.J., Mering, Christian v., 2019. STRING v11:
- 709 protein-protein association networks with increased coverage, supporting functional
- discovery in genome-wide experimental datasets. Nucleic Acids Research 47, D607-D613.
- van Os, J., Linscott, R.J., Myin-Germeys, I., Delespaul, P., Krabbendam, L., 2009. A
- 512 systematic review and meta-analysis of the psychosis continuum: evidence for a psychosis
- proneness–persistence–impairment model of psychotic disorder. Psychological Medicine 39,
- 714 179-195.
- 715 Warren, N., O'Gorman, C., Horgan, I., Weeratunga, M., Halstead, S., Moussiopoulou, J.,
- 716 Campana, M., Yakimov, V., Wagner, E., Siskind, D., 2024. Inflammatory cerebrospinal fluid
- 717 markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69
- studies with 5710 participants. Schizophrenia Research 266, 24-31.
- 719 World Health Organization Division of Mental Health, 1994. Schedules for Clinical
- 720 Assessment in Neuropsychiatry. American Psychiatric Press (on behalf of World Health
- 721 Organization), Washington, DC.
- Xia, Q.-R., Zhang, C., Liang, J., Xu, Y.-Y., 2019. The association of functional polymorphism
- of matrix metalloproteinase-9 gene (rs3918242) with schizophrenia: a meta-analysis.
- 724 International Journal of Psychiatry in Clinical Practice 23, 207-214.

Tsang et al.

- Zammit, S., Kounali, D., Cannon, M., David, A.S., Gunnell, D., Heron, J., Jones, P.B., Lewis,
- S., Sullivan, S., Wolke, D., Lewis, G., 2013. Psychotic Experiences and Psychotic Disorders
- 727 at Age 18 in Relation to Psychotic Experiences at Age 12 in a Longitudinal Population-Based
- 728 Cohort Study. American Journal of Psychiatry 170, 742-750.
- Zuber, V., Grinberg, N.F., Gill, D., Manipur, I., Slob, E.A.W., Patel, A., Wallace, C., Burgess,
- 730 S., 2022. Combining evidence from Mendelian randomization and colocalization: Review
- and comparison of approaches. The American Journal of Human Genetics 109, 767-782.

